Next Potential Big ADC Player? Korean Firms Take It Up A Notch

Most Assets Still Early Stage

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

Will Korean ADC Players Catch Up With Major Global Players? • Source: Shutterstock

While the global biopharma industry saw lackluster deal-making activity in 2022, transactions involving antibody-drug conjugates (ADCs) continued to rise amid the global commercial success of Daiichi Sankyo Co., Ltd./AstraZeneca PLC's Enhertu (trastuzumab deruxtecan) for breast and other cancers.

Korean firms meanwhile are also playing an increasing important role in the ADC arena, highlighted by LegoChem Biosciences, Inc.'s...